Correction to: Clin Pharmacokinet (2018) 57: [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] https://doi.org/10.1007/s40262-017-0545-1
Page 40, column 2, para 1 which reads as For each simulation, PK profiles from 1000 subjects were simulated based on a titration scheme of 100 lg for 6 days, 200 lg for 6 days and 400 lg for 6 days to reach the cebranopadol target dose of 600 lg. Median values of maximum concentration at steady state (C max,ss ) and area under the curve at steady state (AUC ss ) were calculated. The time to reach steady state was calculated as the time point when the AUC reaches 98% of the AUC at absolute steady state, e.g. maximum AUC value during a duration of 50 days.
should read For each deterministic simulation (i.e., the interindividual variability was fixed to 0), one subject PK profile was simulated based on an optimized titration scheme to reach the cebranopadol target dose of 600 lg (100 lg of 6 days, 200 lg of 6 days, 400 lg of 6 days and 600 lg). The steady-state was defined to be achieved on Day 40 in the simulation to calculate the values of maximum concentration at steady state (C max,ss ) and area under the curve at steady state (AUC s,ss ) as reported in Table 14 .
Page 45, column 2, para 4 which reads as As shown in Table 14 , the impact of age and body weight on C max,ss and AUC ss was lower than 3% with respect to the values of the typical patient considered as reference, whereas the impact of lower CrCl values accounted for increases in C max,ss and AUC ss up to 30 and 34% in the investigated range, respectively. Females had 13% higher C max,ss and 17% higher AUC ss than males due to the fact that sex significantly correlated with clearance (Table 14) . As the histogram in Fig. 4 shows, a considerable overlap exists between the distributions of male and female clearances.
should read As shown in Table 14 , the impact of age and body weight on C max,ss and AUC ss was lower or equal to 1% with respect to the values of the typical patient considered as reference, whereas the impact of lower CrCl values accounted for increases in C max,ss and AUC ss up to 28 and 34% in the investigated range, respectively. Females had 14% higher C max,ss and 17% higher AUC ss than males due to the fact that sex significantly correlated with clearance (Table 14) . As the histogram in Fig. 4 shows, a considerable overlap exists between the distributions of male and female clearances.
Page 45, column 2, para 5 and page 46, column 1, para 1 which read as The simulations also indicated that low back pain/osteoarthritis and diabetic polyneuropathy patient populations can have up to 29.5% higher C max,ss and AUC ss values compared with healthy subjects (Table 14) . (Table 14) .
Page 46, The titration scheme to reach cebranopadol 600 lg is defined as cebranopadol 100 lg for 6 days, cebranopadol 200 lg for 6 days, cebranopadol 400 lg for 6 days and cebranopadol 600 lg
The reference values for the covariates, defined as the median values for continuous covariates and the most frequent category for categorical covariates, except disease status, were: sex = male, formulation = tablet, CYP2C9 status = unknown, disease status = LBP and OA patients, age (years) = 55, CrCl (mL/min) = 106.4, body weight (kg) = 82, ALT (units/L) = 19
ALT alanine transferase, AUC s,ss area under the plasma concentrationtime curve for one 24 h dosing interval at steady state, C max,ss maximum plasma concentration at steady state, CrCl creatinine clearance, CYP cytochrome P450, DPN diabetic polyneuropathy, LBP low back pain, OA osteoarthritis Page 49, column 2, para 2, lines 4-5 which read as …exceed an overall 35% change in cebranopadol exposure in the investigated dose range. should read …exceed an overall 35% change in cebranopadol exposure in the investigated dose range except for bunionectomy patients. Page 49, column 2, para 4, lines 2-3 which read as …cebranopadol is comparable in healthy subjects and patients. should read …cebranopadol is comparable in healthy subjects and in patients with chronic pain.
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